<DOC>
	<DOC>NCT00955084</DOC>
	<brief_summary>The primary objective of this study is to allow rollover of the two remaining subjects from the other XL999 studies to continue to receive XL999. The secondary objectives of this study are as follows: - To evaluate tumor response after long term repeat administration of XL999 in two subjects rolled over from other XL999 studies. - To characterize the long term safety and tolerability of XL999 after repeat administration in two subjects rolled over from other XL999 studies. - To characterize the long term effects of XL999 on cardiac function after repeat administration in two subjects rolled over from other XL999 studies.</brief_summary>
	<brief_title>Maintenance Study on the Long Term Safety of XL999</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>The subject is currently enrolled in Protocols XL999001 or XL999204 The subject has received XL999 for at least one year prior to enrollment Per the respective parent XL999 protocol, the subject is eligible to continue to receive XL999 in the absence of progressive disease (PD) or unacceptable drugrelated toxicity Progressive disease Any development(s) that would meet the exclusion criteria from the subject's respective XL999 protocol (XL999001 or XL999204)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>